CALL/AMGEN/450/0.1/16.01.26 | Real-time BOERSE MUENCHEN 11:26:28 26/06/2024 BST | ||
| 0.78 EUR | -7.14% |
|
| Current month | +21.74% | ||
| 1 month | +12.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 26/06/24 | 0.78 | -7.14% |
| 25/06/24 | 0.84 | +20.00% |
| 24/06/24 | 0.7 | +6.06% |
| 21/06/24 | 0.66 | -1.49% |
| 20/06/24 | 0.67 | +8.06% |
Real-time BOERSE MUENCHEN
Last update June 26, 2024 at 11:26 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Goldman Sachs |
| WKN | GG323K |
| ISIN | DE000GG323K2 |
| Date issued | 09/02/2024 |
| Strike | 450 $ |
| Maturity | 16/01/2026 (570 Days) |
| Parity | 10 : 1 |
| Emission price | 0.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.97 € |
|---|---|
| Lowest since issue | 0.233 € |
| Spread | 0.1 € |
| Spread % | 11.76% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
319.3
USD
Average target price
316.4
USD
Spread / Average Target
-0.90%
- Stock Market
- Warrants
- Warrant
